Department of Neurosurgery, Humanitas Research Hospital IRCCS, via Manzoni 56, 20089, Rozzano, MI, Italy.
Department of Neurological Surgery, University of Virginia Health Science Center, Charlottesville, VA, USA.
Neurosurg Rev. 2022 Feb;45(1):71-80. doi: 10.1007/s10143-021-01561-x. Epub 2021 May 12.
Medial thalamotomy using stereotactic radiosurgery (SRS) is a potential treatment for intractable pain. However, the ideal treatment parameters and expected outcomes from this procedure remain unclear. The aim of this systematic review is to provide further insights on medial thalamotomy using SRS, specifically for intractable pain. A systematic review was performed to identify all clinical articles discussing medial thalamotomy using SRS for intractable pain. Only studies in which SRS was used to target the medial thalamus for pain were included. For centers with multiple publications, care was taken to avoid recounting individual patients. The literature review revealed six studies describing outcomes of medial thalamotomy using SRS for a total of 125 patients (118 included in the outcome analysis). Fifty-two patients were treated for cancer pain across three studies, whereas five studies included 73 patients who were treated for nonmalignant pain. The individual studies demonstrated initial meaningful pain reduction in 43.3-100% of patients, with an aggregate initial meaningful pain reduction in 65 patients (55%) following SRS medial thalamotomy. This effect persisted in 45 patients (38%) at the last follow-up. Adverse events were observed in six patients (5%), which were related to radiation in five patients (4%). Medial thalamotomy using SRS is effective for select patients with treatment-resistant pain and is remarkably safe when modern radiation delivery platforms are used. More posteriorly placed lesions within the medial thalamus were associated with better pain relief. More studies are warranted to shed light on differences in patient responses.
立体定向放射外科(SRS)介导的内侧丘脑切开术是治疗难治性疼痛的一种潜在疗法。然而,该手术的理想治疗参数和预期结果仍不清楚。本系统综述旨在提供关于 SRS 介导的内侧丘脑切开术的进一步深入了解,特别是针对难治性疼痛。本系统综述旨在确定所有讨论 SRS 介导的内侧丘脑切开术治疗难治性疼痛的临床文章。仅纳入使用 SRS 靶向内侧丘脑治疗疼痛的研究。对于有多篇出版物的中心,注意避免重复计算个别患者。文献综述共发现了 6 项研究,这些研究描述了使用 SRS 进行内侧丘脑切开术治疗难治性疼痛的结果,共涉及 125 例患者(118 例纳入结局分析)。有 3 项研究中的 52 例患者因癌症疼痛接受治疗,5 项研究中的 73 例患者因非恶性疼痛接受治疗。个别研究表明,SRS 介导的内侧丘脑切开术后,43.3%-100%的患者初始疼痛显著减轻,65 例患者(55%)初始疼痛显著减轻,随后进行 SRS 介导的内侧丘脑切开术。45 例患者(38%)在最后一次随访时仍有疼痛缓解。6 例患者(5%)观察到不良反应,其中 5 例患者(4%)与放疗相关。SRS 介导的内侧丘脑切开术对治疗抵抗性疼痛的特定患者有效,并且当使用现代放射治疗平台时,安全性显著提高。内侧丘脑内更靠后的病变与更好的疼痛缓解相关。需要更多的研究来阐明患者反应的差异。